natgillin/translations-raw huggingface dataset:
Docetaxel Accord concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution. 
Docetaksel Accord koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje k raztopini za infundiranje.
• hair loss: in most cases normal hair growth should return. 
• izguba las in dlak: večinoma se obnovi njihova normalna rast; v nekaterih primerih (neznana pogostnost) so bili opisani primeri trajne izgube las in dlak
There is no relevant use of docetaxel in the paediatric population in the indications breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma. 
Zdravilo docetaksel ni primerno za uporabo pri pediatrični populaciji nima za indikacije rak dojke, nedrobnocelični pljučni rak, rak prostate, karcinom želodca in rak glave in vratu, ne vključujoč manj diferenciiran nazofaringealni karcinom tipa II oz. III.
• Then, inject via a single injection (one shot) into a 250 ml infusion bag containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
• Potem jo vbrizgajte preko ene injekcije (en odmerek) v 250-ml infuzijsko vrečko, ki vsebuje 5 % raztopino glukoze ali raztopino natrijevega klorida 9 mg/ml (0,9 %) za infundiranje.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO perfomance status 0 or 1, were randomised to one of two treatment arms. 
V tej študiji so 358 bolnikov z inoperabilnim lokalno napredovalim SCCHN in stanjem zmogljivosti po WHO 0 ali 1 randomizirali v enega od dveh terapevtskih krakov.
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU *Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO) **Logrank test *** Chi-square test 
Razmerje tveganj manj kot 1 je v prid kombinaciji docetaksel + cisplatin + 5-FU *Model po Cox-u (prilagoditev glede na mesto primarnega tumorja, klinični stadij T in N in stanje zmogljivosti po WHO) **Log-rank test ***Hi - kvadrat test
The infusion solution must not be coupled to the infusion set for more than 6 h at 25°C. 
Raztopina za infundiranje ne sme biti priključena na infuzijski set dlje kot 6 ur pri temperaturi do 25°C.
For those patients with serum bilirubin > ULN 
Pri bolnikih, ki imajo serumski bilirubin > ULN in/ali ALT in
It is important that you read the entire contents of this guide prior to the preparation of the Docetaxel Accord infusion solution. 
Pomembno je, da pred pripravo osnovne raztopine zdravila Docetaksel Accord ali raztopine za infundiranje zdravila Docetaksel Accord v celoti preberete ta navodila.
- For the treatment of early breast cancer with or without lymph node involvement, docetaxel could be administered in combination with doxorubicin and cyclophosphamide. 
- Za zdravljenje zgodnjega raka dojke brez ali s prizadetostjo bezgavk se docetaksel lahko daje v kombinaciji z doksorubicinom in ciklofosfamidom.
In combination with cisplatin For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm3, or in patients who experience febrile neutropenia, or in patients with serious non-haematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/m2. 
V kombinaciji s cisplatinom Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25.000 celic/mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih ciklusih zmanjšati na 65 mg/m2.
Eye disorders Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported. 
Opisani so bili zelo redki primeri prehodnih motenj vida (bliskanje, bliskajoča svetloba, skotomi), ki so se praviloma pojavili med infundiranjem zdravila in v povezavi s preobčutljivostnimi reakcijami.
Based on a population pharmacokinetic analysis, there are no special instructions for use in the elderly. 
Za uporabo pri starostnikih glede na analizo farmakokinetike na populaciji ni posebnih navodil.
The most commonly reported adverse reactions of docetaxel alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness. 
Najpogosteje poročani neželeni učinki docetaksela samega so: zmanjšanje števila rdečih ali belih krvnih celic, alopecija, slabost, bruhanje, razjede v ustih, driska in utrujenost.
Patients with operable node-negative breast cancer eligible to receive chemotherapy (GEICAM 9805) 
Bolnice z operabilnimrakom dojke znegativnimi bezgavkami, primerne za prejemanje kemoterapije (GEICAM 9805)
As with all parenteral products, Docetaxel Accord infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded. 
Tako kot vsa zdravila za parenteralno uporabo je treba raztopino za infundiranje Docetaksel Accord pred uporabo pregledati; če vsebuje precipitat, jo je treba zavreči.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm-GEICAM study. 
Spodnja preglednica kaže, da se je incidenca nevtropenije, febrilne nevtropenije in nevtropeničnih okužb 4. stopnje zmanjšala pri bolnicah, ki so prejemale primarno profilakso z G-CSF, potem ko je ta postala obvezna v kraku TAC - študija GEICAM.
Dose adjustments during treatment 
Prilagajanje odmerka med zdravljenjem:
• For patients developing the second appearance of Grade 2 toxicity, or the first appearance of Grade 3 toxicity, at any time during the treatment cycle, delay treatment until resolved to Grade 0-1 and then resume treatment with docetaxel 55 mg/m2. 
• Pri bolnikih, pri katerih se drugič pojavijo toksični učinki 2. stopnje ali prvič učinki 3. stopnje kadarkoli med ciklusom zdravljenja, zdravljenje odložite, dokler se ne zmanjšajo na stopnjo od 0 do 1, nato zdravljenje nadaljujte z docetakselom 55 mg/m2.
Overall survival (Primary end-point): Median survival (months) 1-year Survival (%) 2-year Survival (%) 
statistična analiza celotno preživetje (primarna končna točka) mediana preživetja (meseci)
At the median follow-up time of 77 months significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated. 
Po mediano 77 mesecih spremljanja je bilo dokazano, da je preživetje brez bolezni v kraku TAC značilno daljše kot v kraku FAC.
To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy. 
Vsebnost etanola je treba upoštevati tudi pri nosečnicah, doječih ženskah, otrocih in skupinah z velikim tveganjem, npr. pri bolnikih z boleznijo jeter ali epilepsijo.
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution. 
Docetaksel Accord 20 mg/4 ml koncentrat za raztopino za infundiranje NE POTREBUJE predhodnega redčenja z vehiklom in je pripravljen za dodajanje raztopini za infundiranje.
• Docetaxel 75 mg/m2 every 3 weeks for 10 cycles. 
• docetaksel 75 mg/m2 vsake 3 tedne, 10 ciklov.
The required volume of Docetaxel Accord concentrate for solution for infusion must be injected via a single injection (one shot) into a 250 ml infusion bag containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
Potrebno količino koncentrata za raztopino za infundiranje Docetaksel Accord je treba vbrizgati preko ene injekcije (en odmerek) v 250-ml infuzijsko vrečko ali steklenico, ki vsebuje 5 % raztopino glukoze ali raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate ≥ 10% higher in patients who were 65 years of age or greater compared to younger patients. 
Pri bolnikih, zdravljenih z docetakselom vsake tri tedne, ki so bili starejši od 65 let, je bila incidenca pojavljanja z zdravljenjem povezanih sprememb na nohtih  10 % večja v primerjavi z mlajšimi bolniki.
Docetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: 
Zdravilo Docetaksel Accord je v kombinaciji z doksorubicinom in ciklofosfamidom indicirano za adjuvantno zdravljenje bolnic:
Efficacy of docetaxel in the induction treatment of patients with inoperable locally advanced SCCHN (Intent-to-treat analysis) 
Učinkovitost zdravila docetaksel za indukcijsko zdravljenje bolnikov z inoperabilnim lokalno napredovanim SCCHN (analiza z namenom zdravljenja)
An open-label, multicentre, randomised phase III study was conducted to compare docetaxel monotherapy and paclitaxel in the treatment of advanced breast cancer in patients whose previous therapy should have included an anthracycline. 
Narejena je bila odprta multicentrična randomizirana študija III. faze za primerjavo monoterapije docetaksela in paklitaksela pri zdravljenju napredovalega raka na dojki pri bolnicah, katerih predhodno zdravljenje je moralo vključevati nek antraciklin.
Data from one multicentre, randomised, controlled phase III clinical study support the use of docetaxel in combination with capecitabine for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline. 
Podatki multicentrične, randomizirane, kontrolirane klinične študije III. faze podpirajo uporabo docetaksela v kombinaciji s kapecitabinom za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke po neuspehu citotoksične kemoterapije, ki je vključevala antraciklin.
Constipation (severe: 0.2%); Abdominal pain (severe: 1%); Gastrointestinal haemorrhage (severe: 0.3%) 
zaprtje (hudo 0,2 %), bolečine v trebuhu (hude 1 %), gastrointestinalna krvavitev (huda 0,3 %)
For breast and non-small cell lung cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg twice daily) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. 
Pri zdravljenju raka dojke in nedrobnoceličnega pljučnega raka lahko 3-dnevna premedikacija s peroralnim kortikosteroidom, npr. deksametazonom 16 mg na dan (npr. 8 mg 2-krat na dan), ki se začne 1 dan pred aplikacijo docetaksela, zmanjša pogostnost in izrazitost zastajanja tekočine ter izrazitost preobčutljivostnih reakcij, če ni kontraindicirana.
• non-Hodgkin lymphoma (a cancer affecting the immune system) and other cancers may occur in patients who are treated with docetaxel together with certain other anticancer treatments. 
• reakcije na mestu injiciranja na mestu predhodne reakcije ne-Hodgkinov limfom (rak ki napade imunski sistem) in druge vrste raka se lahko pojavijo pri bolnikih, ki se zdravijo z docetakselom v kombinaciji z nekatermi drugimi zdravili proti raku.
• Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles. 
• docetaksel 30 mg/m2 aplicirano tedensko prvih 5 tednov 6 tedenskega cikla, ki se ponovi v 5-ih ciklih.
Docetaxel Accord 160 mg/8 ml contains 
Docetaksel Accord 160 mg/8 ml vsebuje
Excipients: polysorbate 80, ethanol anhydrous (see leaflet for further information) and citric acid anhydrous. 
Pomožne snovi: polisorbat 80, brezvodni etanol (za dodatne informacije glejte navodilo za uporabo) in brezvodna citronska kislina.
A total of 1006 patients with KPS ≥ 60 were randomised to the following treatment groups: 
V spodnje skupine zdravljenja je bilo randomiziranih skupno 1006 bolnikov z zmogljivostjo po Karnofskem  60:
One large randomised phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with doxorubicin (50 mg/m2) in combination with docetaxel (75 mg/m2) (AT arm) versus doxorubicin (60 mg/m2) in combination with cyclophosphamide (600 mg/m2) (AC arm). 
Opravljena je bila ena velika randomizirana študija III. faze, ki je vključevala 429 predhodno nezdravljenih bolnic z metastatsko boleznijo; v njej so kombinacijo doksorubicina (50 mg/m2) in docetaksela (75 mg/m2) (krak AT) primerjali s kombinacijo doksorubicina (60 mg/m2) in ciklofosfamida (600 mg/m2) (krak AC).
Efficacy of docetaxel in the induction treatment of patients with locally advanced SCCHN (Intent-to-treat analysis) 
Učinkovitost docetaksela v indukcijskem zdravljenju bolnikov z lokalno napredovalim SCCHN (analiza z-namenom-zdravljenja)
• Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomised, multicentre open-label, phase III study (TAX324). 
• Indukcijska kemoterapija in nato kemoradioterapija (TAX324) Varnost in učinkovitost docetaksela za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu (SCCHN) so ocenili v randomizirani multicentrični odprti študiji III. faze (TAX324).
The most frequently reported symptoms were flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills. 
Najpogosteje opisani simptomi so vročinski oblivi, izpuščaj s srbenjem ali brez njega, tiščanje v prsih, bolečine v hrbtu, dispneja in zvišanje telesne temperature ali mrzlica.
A multicentre, open-label, randomised study was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. 
Opravljena je bila multicentrična, odprta, randomizirana študija za oceno varnosti in učinkovitosti docetaksela pri zdravljenju bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki za metastatsko bolezen še niso prejemali kemoterapije.
Docetaxel in combination with doxorubicin and cyclophosphamide: adjuvant therapy 
Docetaksel v kombinaciji z doksorubicinom in ciklofosfamidom: adjuvantno zdravljenje
Patients with hepatic impairment Based on pharmacokinetic data with docetaxel at 100 mg/m2 as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m2 (see sections 4.4 and 5.2). 
Bolniki z okvaro jeter Glede na farmakokinetične podatke o monoterapiji z docetakselom v odmerku 100 mg/m2 je priporočljivi odmerek docetaksela za bolnike, ki imajo transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno zgornjo mejo normalnega območja (ULN) in alkalno fosfatazo nad 2,5-kratno ULN, 75 mg/m2 (glejte poglavji 4.4 in 5.2).
- The other ingredients are polysorbate 80, ethanol anhydrous (see section 2) and citric acid anhydrous. 
Pomožne snovi so polisorbat 80, brezvodni etanol (glejte poglavje 2) in brezvodna citronska kislina.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions. 
Docetaksel je zdravilo z delovanjem na novotvorbe (citostatik) in tako kot pri ravnanju z drugimi potencialno toksičnimi spojinami je tudi med rokovanjem z njim in med pripravo njegovih raztopin potrebna previdnost.
- For the treatment of lung cancer, docetaxel could be administered either alone or in combination with cisplatin. 
- Za zdravljenje pljučnega raka se docetaksel lahko uporablja sam ali v kombinaciji s cisplatinom.
Heart failure has been observed in patients receiving docetaxel in combination with trastuzumab, particularly following anthracycline (doxorubicin or epirubicin) -containing chemotherapy. 
Pri bolnicah, ki so prejemale docetaksel v kombinaciji s trastuzumabom so opazovali srčno popuščanje, še posebno, če je zdravljenje sledilo kemoterapiji z antraciklinom (doksorubicin ali epirubicin).
Docetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. 
Zdravilo Docetaksel Accord je v kombinaciji s prednizonom ali prednizolonom indicirano za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
Docetaxel Accord 80 mg/4 ml contains 
Docetaksel Accord 80 mg/4 ml vsebuje
TAC-treated patient subsets according to prospectively defined major prognostic factors were analysed in the primary analysis (at the median follow-up time of 77 months) (see table below): 
Podskupine bolnic, zdravljenih s TAC, so analizirali po prospektivno opredeljenih prognostičnih dejavnikih v primarni analizi (po mediano 77 mesecih spremljanja (glejte spodnjo preglednico): Analize podskupine - adjuvantno zdravljenje bolnic v študiji raka dojke z negativnimi bezgavkami (analiza z-namenom-zdravljenja)
Docetaxel in combination with doxorubicin 
Docetaksel v kombinaciji z doksorubicinom
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period. 
V kombinaciji s kapecitabinom je priporočeni odmerek docetaksela 75 mg/m2 na tri tedne, kombiniran s kapecitabinom 1.250 mg/m2 dvakrat na dan (v 30 minutah po obroku) 2 tedna, čemur sledi 1-tedenski premor.
Diarrhoea grade 3 First episode: reduce 5-FU dose by 20%. 
Prilagoditev odmerka driska 3. stopnje Prvi pojav: zmanjšajte odmerek 5-FU za 20 %.
DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product which contains only 1 vial of concentrate. 
NE UPORABLJAJTE drugih zdravil z docetakselom, ki vsebujejo 2 viali (koncentrat in vehikel) s tem zdravilom, ki vsebuje samo 1 vialo koncentrata.
For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m2 as a single agent. 
Za zdravljenje po neuspehu predhodne, na platini osnovane kemoterapije, je priporočeni odmerek 75 mg/m2 v monoterapiji.
• pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath). 
• plučna fibroza (brazgotinjenje in zadebelitve v pljučih, težko dihanje/kratka sapa)
In alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m2 every 3 weeks). 
Pri bolnicah z neuspelim alkilirajočim zdravljenjem so docetaksel primerjali z doksorubicinom (75 mg/m2 na 3 tedne).
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomised study (TAX323). 
• Indukcijska kemoterapija in nato radioterapija (TAX323) Varnost in učinkovitost zdravila docetaksel za indukcijsko zdravljenje bolnikov s skvamoznoceličnim karcinomom glave in vratu (SCCHN) so ocenjevali v multicentrični odprti randomizirani študiji III. faze (TAX323).
Data from a multicentre open-label randomised trial support the use of docetaxel for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy. 
Podatki multicentričnega, odprtega randomiziranega preskušanja podpirajo uporabo zdravila docetaksel za adjuvantno zdravljenje bolnic z operabilnim rakom dojke z negativnimi bezgavkami, primernih za prejemanje kemoterapije.
• 1,312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively. 
• 1.312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaksela, 121 pa jih je prejemalo 75 mg/m².
Recommended dose modifications for toxicities in patients treated with docetaxel in combination with cisplatin and 5-fluorouracil (5-FU): 
Priporočene prilagoditve odmerka v primeru toksičnih učinkov pri bolnikih, ki prejemajo docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (5-FU): Toksičen učinek
Docetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. 
Zdravilo Docetaksel Accord je v kombinaciji s cisplatinom in 5-fluorouracilom indicirano za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
Tumour response rate (%) 95% CI p-value* †Stratified log-rank test *Threshold for statistical significance = 0.0175 **PSA: Prostate-Specific Antigen 
95 % IZ p-vrednost†* število bolnikov odzivnost na PSA** (%) 95 % IZ p-vrednost* število bolnikov odzivnost na bolečino (%) 95 % IZ p- vrednost* število bolnikov odzivnost tumorja (%) 95 % IZ p- vrednost* †Stratificiran log-rang test *Prag statistične značilnosti = 0,0175 **PSA: prostatični specifični antigen
(G3/4: 1.2%) 
(S3/4:0,2 %)
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m2 as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m2 twice daily for 2 weeks followed by 1-week rest period). 
V tem preskušanju so 255 bolnic randomizirali na zdravljenje z docetakselom (75 mg/m2 v 1-urni intravenski infuziji na 3 tedne) in kapecitabinom (1.250 mg/m2 dvakrat na dan 2 tedna s sledečim 1-tedenskim premorom).
Read the package leaflet before use Single use vial 
Pred uporabo preberite priloženo navodilo!
mostly associated with dehydration, vomiting and pneumonia. 
Opisani so bili primeri hiponatriemije, večinoma povezani z dehidracijo, bruhanjem in pljučnico.
Marketing Authorisation Holder Accord Healthcare S.L.U. 
Imetnik dovoljenja za promet z zdravilom in proizvajalec Imetnik dovoljenja za promet z zdravilom Accord Healthcare S.L.U.
A total of 445 patients with KPS > 70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F) (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 per day for 5 days). 
Skupaj je bilo zdravljenih 445 bolnikov z oceno zmogljivosti po Karnofskem > 70; prejemali so bodisi docetaksel (T) (75 mg/m2 1. dan) v kombinaciji s cisplatinom (C) (75 mg/m2 1. dan) in 5-fluorouracilom (F) (750 mg/m2 na dan, 5 dni), bodisi cisplatin (100 mg/m2 1. dan) in 5fluorouracil (1000 mg/m2 na dan, 5 dni).
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg twice daily) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4). 
Pri zdravljenju raka dojke, nedrobnoceličnega pljučnega raka, raka želodca ter raka glave in vratu lahko kot premedikacijo dajemo peroralne kortikosteroide, kot je deksametazon 16 mg na dan (npr. 8 mg dvakrat na dan v trajanju treh dni, in sicer 1 dan pred aplikacijo docetaksela, razen v primeru kontraindikacij (prosimo, glejte poglavje 4.4).
A total of 449 patients were randomised to receive either docetaxel monotherapy 100 mg/m2 as a 1 hour infusion or paclitaxel 175 mg/m2 as a 3 hour infusion. 
Skupaj 449 bolnic je bilo randomiziranih bodisi na monoterapijo z docetakselom 100 mg/m2 v 1-urni infuziji bodisi na paklitaksel 175 mg/m2 v